Real-World Data Show Suboptimal Efficacy With AZA in Treatment-Naïve High-Risk MDS

Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).

Related Keywords

,Eastern Cooperative Oncology Group ,Clinical Lymphoma ,Myelodysplastic Syndromes ,Mds ,Azacytidine ,First Line Azacytidine ,